Voyager Therapeutics released longer-term data from its ongoing Phase Ib clinical trial of VY-AADC in advanced Parkinson’s disease. Source: BioSpace

Seven months after Prevail Therapeutics launched, the company has secured $75 million in Series A financing to support the development of gene therapies for Parkinson’s disease. Source: BioSpace

Sanofi SA and Evotec AG have teamed up to form an infectious disease research and development program. Source: BioSpace

Cyteir Therapeutics snagged $29 million and a new chief executive officer as the company pushes forward to develop small-molecule inhibitors in the fight against cancer. Source: BioSpace

This week Pfizer notified the Bay Area-based company of its intent to terminate its five-year-old oncology collaboration. Source: BioSpace

John Reed, who for five years has led Roche’s Pharma Research and Early Development (pRED) research group, is stepping down for personal reasons. Source: BioSpace

U.S. insurer Cigna is acquiring pharmacy benefits manager Express Scripts for approximately $67 billion. Source: BioSpace

JW Therapeutics, a clinical stage biopharma company founded by Juno Therapeutics and WuXi AppTec Group, has closed a Series A financing worth $90 million. Source: BioSpace

The U.S. Food and Drug Administration has approved Trogarzo (ibalizumab), the first HIV-1 inhibitor for patients with multi-drug resistant HIV-1. Source: BioSpace

Seattle Genetics dosed its first patient with an early-stage treatment for patients with relapsed or refractory multiple myeloma (MM). Source: BioSpace